These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 15182793)

  • 21. The cyclooxygenase-2-selective inhibitors rofecoxib and celecoxib prevent colorectal neoplasia occurrence and recurrence.
    Rahme E; Barkun AN; Toubouti Y; Bardou M
    Gastroenterology; 2003 Aug; 125(2):404-12. PubMed ID: 12891542
    [TBL] [Abstract][Full Text] [Related]  

  • 22. COX-2-specific inhibition: implications for clinical practice.
    Pascucci RA
    J Am Osteopath Assoc; 1999 Nov; 99(11 Suppl):S18-22. PubMed ID: 10643177
    [TBL] [Abstract][Full Text] [Related]  

  • 23. COX-2 selective inhibitors in the treatment of arthritis: a rheumatologist perspective.
    Hochberg MC
    Curr Top Med Chem; 2005; 5(5):443-8. PubMed ID: 15974939
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Blood pressure destabilization and related healthcare utilization among hypertensive patients using nonspecific NSAIDs and COX-2-specific inhibitors.
    Zhao SZ; Burke TA; Whelton A; von Allmen H; Henderson SC
    Am J Manag Care; 2002 Oct; 8(15 Suppl):S401-13. PubMed ID: 12416790
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The new NSAIDs: cox-2 inhibitors.
    Capriotti T
    Medsurg Nurs; 2000 Dec; 9(6):313-7. PubMed ID: 11904867
    [No Abstract]   [Full Text] [Related]  

  • 26. The cox-2 inhibitors.
    Strassels S
    J Mass Dent Soc; 1999; 48(3):43-4. PubMed ID: 10808349
    [No Abstract]   [Full Text] [Related]  

  • 27. Comparison of conventional NSAIDs and cyclooxygenase-2 inhibitors in outpatients.
    Modica M; Vanhems P; Tebib J
    Joint Bone Spine; 2005 Oct; 72(5):397-402. PubMed ID: 16129642
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults.
    Solomon DH; Schneeweiss S; Glynn RJ; Kiyota Y; Levin R; Mogun H; Avorn J
    Circulation; 2004 May; 109(17):2068-73. PubMed ID: 15096449
    [TBL] [Abstract][Full Text] [Related]  

  • 29. COX-2 inhibitors. Magic bullets or merely mortal?
    Harv Health Lett; 2000 Feb; 25(4):4. PubMed ID: 10637015
    [No Abstract]   [Full Text] [Related]  

  • 30. The new COX-2 inhibitors: rofecoxib (Vioxx) and celecoxib (Celebrex).
    Wynn RL
    Gen Dent; 2000; 48(1):16-20. PubMed ID: 11199547
    [No Abstract]   [Full Text] [Related]  

  • 31. COX-2 specific inhibitors offer improved advantages over traditional NSAIDs.
    Urban MK
    Orthopedics; 2000 Jul; 23(7 Suppl):S761-4. PubMed ID: 10914695
    [TBL] [Abstract][Full Text] [Related]  

  • 32. COX-2 inhibitors.
    Brooks PM; Day RO
    Med J Aust; 2000 Oct; 173(8):433-6. PubMed ID: 11090038
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Specific inhibitors of cyclooxygenase type 2] ].
    Tomasová-Studýnková J
    Vnitr Lek; 2002 May; 48(5):403-8. PubMed ID: 12061207
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study.
    Silverstein FE; Faich G; Goldstein JL; Simon LS; Pincus T; Whelton A; Makuch R; Eisen G; Agrawal NM; Stenson WF; Burr AM; Zhao WW; Kent JD; Lefkowith JB; Verburg KM; Geis GS
    JAMA; 2000 Sep; 284(10):1247-55. PubMed ID: 10979111
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [The coxibs, third generation anti-inflammatories].
    Sternon J
    Rev Med Brux; 2001 Apr; 22(2):100-5. PubMed ID: 11388024
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Drug switching patterns among patients with rheumatoid arthritis and osteoarthritis using COX-2 specific inhibitors and non-specific NSAIDs.
    Zhao SZ; Wentworth C; Burke TA; Makuch RW
    Pharmacoepidemiol Drug Saf; 2004 May; 13(5):277-87. PubMed ID: 15133778
    [TBL] [Abstract][Full Text] [Related]  

  • 37. COX-2-specific inhibitors: prescribing patterns in a large managed care health system and strategies to minimize costs.
    Weideman RA; Kelly KC; Kelley CL; Cryer B
    Am J Manag Care; 2002 Oct; 8(10):869-77. PubMed ID: 12395955
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A comparison of adverse renovascular experiences among osteoarthritis patients treated with rofecoxib and comparator non-selective non-steroidal anti-inflammatory agents.
    Gertz BJ; Krupa D; Bolognese JA; Sperling RS; Reicin A
    Curr Med Res Opin; 2002; 18(2):82-91. PubMed ID: 12017215
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Uptake of COX-2 selective inhibitors and influence on NSAID prescribing in Northern Ireland.
    Girvin B; Rafferty T; Stevenson MR; Johnston GD
    Pharmacoepidemiol Drug Saf; 2004 Mar; 13(3):153-7. PubMed ID: 15072114
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Specific inhibitors of cyclooxygenase-2 (COX-2): current knowledge and perspectives].
    Rioda WT; Nervetti A
    Acta Biomed Ateneo Parmense; 2001; 72(3-4):55-64. PubMed ID: 11889908
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.